PT3679016T - Formas sólidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin- 2-il)-n-benzilacetamida - Google Patents

Formas sólidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin- 2-il)-n-benzilacetamida

Info

Publication number
PT3679016T
PT3679016T PT188546881T PT18854688T PT3679016T PT 3679016 T PT3679016 T PT 3679016T PT 188546881 T PT188546881 T PT 188546881T PT 18854688 T PT18854688 T PT 18854688T PT 3679016 T PT3679016 T PT 3679016T
Authority
PT
Portugal
Prior art keywords
benzylacetamide
morpholinoethoxy
pyridin
phenyl
solid forms
Prior art date
Application number
PT188546881T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Atnx Spv Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65517772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3679016(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv Llc filed Critical Atnx Spv Llc
Publication of PT3679016T publication Critical patent/PT3679016T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT188546881T 2017-09-07 2018-09-07 Formas sólidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin- 2-il)-n-benzilacetamida PT3679016T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762555390P 2017-09-07 2017-09-07

Publications (1)

Publication Number Publication Date
PT3679016T true PT3679016T (pt) 2025-12-05

Family

ID=65517772

Family Applications (1)

Application Number Title Priority Date Filing Date
PT188546881T PT3679016T (pt) 2017-09-07 2018-09-07 Formas sólidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin- 2-il)-n-benzilacetamida

Country Status (23)

Country Link
US (4) US10669236B2 (https=)
EP (2) EP4674486A3 (https=)
JP (3) JP7843116B2 (https=)
KR (2) KR102691700B1 (https=)
CN (2) CN111278808B (https=)
AU (2) AU2018330163B2 (https=)
BR (1) BR112020004419A2 (https=)
CA (1) CA3074831A1 (https=)
DK (1) DK3679016T3 (https=)
ES (1) ES3056703T3 (https=)
FI (1) FI3679016T3 (https=)
HR (1) HRP20260002T1 (https=)
IL (2) IL326637A (https=)
LT (1) LT3679016T (https=)
MX (2) MX2020002622A (https=)
PL (1) PL3679016T3 (https=)
PT (1) PT3679016T (https=)
RS (1) RS67706B1 (https=)
SG (1) SG11202001868RA (https=)
SI (1) SI3679016T1 (https=)
SM (1) SMT202500467T1 (https=)
TW (1) TWI815820B (https=)
WO (1) WO2019051147A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP4186890A1 (en) 2021-11-29 2023-05-31 Moehs Ibérica, S.L. Preparation of n-benzyl-2-(5-bromo-pyridin-2-yl)-acetamide for the synthesis of tirbanibulin
CN115010655A (zh) * 2022-07-21 2022-09-06 重庆迈德凯医药有限公司 一种替尼布林的纯化方法
WO2026022219A1 (en) 2024-07-24 2026-01-29 Almirall, S.A. Injectable formulations comprising tirbanibulin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
ES2258142T3 (es) * 2001-05-22 2006-08-16 Pfizer Products Inc. Nueva forma cristalina.
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
ES2382068T3 (es) 2004-12-28 2012-06-05 Kinex Pharmaceuticals, Llc Composiciones y métodos para tratar trastornos de proliferación celular
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
CN101687905A (zh) * 2005-09-13 2010-03-31 西科尔公司 纯罗库溴铵
ES2500165T3 (es) 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
MX2009003405A (es) * 2006-09-28 2009-04-09 Merck & Co Inc Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa.
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) * 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
AU2008253803A1 (en) * 2007-05-22 2008-11-27 Ultimorphix Technolgies B.V. Tenofovir disoproxil hemi-fumaric acid Co-crystal
WO2015069217A1 (en) * 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
CN106810490A (zh) * 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用
FI3592355T3 (fi) 2017-03-10 2026-02-13 Atnx Spv Llc KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa

Also Published As

Publication number Publication date
CN111278808B (zh) 2024-04-26
PL3679016T3 (pl) 2026-03-02
AU2023201010A1 (en) 2023-03-23
US20190071402A1 (en) 2019-03-07
DK3679016T3 (da) 2025-12-15
IL272992A (en) 2020-04-30
JP2025131661A (ja) 2025-09-09
HRP20260002T1 (hr) 2026-02-27
ES3056703T3 (en) 2026-02-24
SMT202500467T1 (it) 2026-03-09
US20220098152A1 (en) 2022-03-31
CN111278808A (zh) 2020-06-12
US20200255380A1 (en) 2020-08-13
CN118439992A (zh) 2024-08-06
AU2018330163A1 (en) 2020-03-26
US10669236B2 (en) 2020-06-02
KR102691700B1 (ko) 2024-08-02
CA3074831A1 (en) 2019-03-14
AU2018330163B2 (en) 2023-02-02
SG11202001868RA (en) 2020-03-30
SI3679016T1 (sl) 2026-04-30
MX2023001805A (es) 2023-03-13
EP3679016B1 (en) 2025-11-05
RU2020112539A3 (https=) 2022-04-19
FI3679016T3 (fi) 2025-12-12
MX2020002622A (es) 2020-10-01
AU2023201010B2 (en) 2024-10-03
EP4674486A3 (en) 2026-03-25
KR20240119192A (ko) 2024-08-06
RS67706B1 (sr) 2026-02-27
KR20200081359A (ko) 2020-07-07
US12215083B2 (en) 2025-02-04
LT3679016T (lt) 2026-02-10
RU2020112539A (ru) 2021-10-08
EP4674486A2 (en) 2026-01-07
JP2020533412A (ja) 2020-11-19
BR112020004419A2 (pt) 2020-09-08
WO2019051147A1 (en) 2019-03-14
US20250115555A1 (en) 2025-04-10
IL326637A (en) 2026-04-01
EP3679016A1 (en) 2020-07-15
EP3679016A4 (en) 2021-09-29
JP2023157909A (ja) 2023-10-26
JP7843116B2 (ja) 2026-04-09
US11230527B2 (en) 2022-01-25
TWI815820B (zh) 2023-09-21
TW201920160A (zh) 2019-06-01

Similar Documents

Publication Publication Date Title
IL280573A (en) 2-(het)aryl-substituted condensed heterocyclic derivatives as pest control agents
SG11202104206SA (en) New heterocyclic compounds
IL279910A (en) Crystal forms of 5-chloro-ene 4-[2-(dimethylphosphoryl)phenyl]-ene 2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidin-2- 4-diamine
IL247833A0 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
IL272992A (en) Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
IL260908B (en) Substituted 2-(het)aryl-imidazolyl-carboxyamides as pest control agents
IL256237B (en) Solid forms of (z) - 4 - (5 - ((3 - benzyl - 4 - oxo - 2 - thioxothiazolidine - 5 - ylidin) methyl) furan - 2 - yl) benzoic acid
SMT202300297T1 (it) Procedimento per la preparazione di n-(5-(4-(4-formil-3-fenil-1h-pirazol-1-il)pirimidin-2-ilammino)-4-metossi-2-morfolinofenil)acrilammide
IL257422A (en) (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
ZA201804482B (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
SI3544976T1 (sl) Hemihidrat proste baze N-(5-(aminosulfonil)-4-metil-1,3-tiazol-2-il)-N-metil-2-(4-(2-(piridi nil)-fenil)-acetamida
ZA202003028B (en) Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
SI3559010T1 (sl) Postopek za pripravo 5-((4-(2-(5-(1-hidroksietil)-2-piridinil)etoksi) fenil)metil)-2,4-tiazolidindiona in soli le-tega
SI3298008T1 (sl) Kristalinična oblika spojine (S)-3-(4-(5-(2-ciklopentil-6-metoksi-piridin-4-IL)-(1,2,4)oksadiazol-3- IL)-2-etil-6-metil-fenoksi)-propan 1,2-diol
HK40131421A (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
SG11202104857PA (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
DK3853219T3 (da) Herbicidt virksomme substituerede phenylpyrimidinhydrazider
NZ716494A (en) Processes and intermediates for the preparation of a pde10 inhibitor
HK40025190A (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
EP3541797A4 (en) 4 - ((6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
PL3247699T3 (pl) Sposób wytwarzania 2-[4-(cyklopropanokarbonylo)fenylo]-2-metylo-propanonitrylu
GB201806488D0 (en) Heterocyclic TADF compounds
GB201808580D0 (en) Heterocyclic compounds
UA98919U (ru) 4-этил-3-(феноксиметил)-5-((2-((5-феноксиметил)-4-фенил-4н-1,2,4-триазол-3-ил)тио)этил)тио)-4н-1,2,4-триазол, проявляющая диуретическую активность